GYRE at a glance
GYRE THERAPEUTICS, INC. (GYRE, SEC CIK 1124105) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as August 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), GYRE THERAPEUTICS, INC. (GYRE) reported revenue of $116.6 million (up 10.2% from FY2024) and net income of $9.9 million. Diluted EPS was $0.02.
- As of September 30, 2026, 15 institutional investment managers tracked by SignalX reported holding GYRE THERAPEUTICS, INC. (GYRE) shares worth $25.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ye Weiguo on June 18, 2026 of 3,000 shares at $6.35 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $116.6M
- +10.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 15 funds
- $25.2M · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the Annual Report and Q2 Quarterly Report risk factors
- Undisclosed risks: unknown or currently immaterial factors could materially adversely affect results
- Clinical-stage business risk: carried-forward Annual Report and Q2 Quarterly Report risks remain applicable
- Regulatory risk: carried-forward SEC-disclosed risks could materially affect financial position
Management Discussion & Analysis
- Revenue $32.9M, up $0.2M or 1% YoY, driven by ETUARY sales despite lower Contiva and Etorel revenue
- Operating loss $1.5M vs operating income $1.5M YoY, operating margin (4.6%) vs 4.6%
- ETUARY best performer, higher sales volumes; Contiva and Etorel worst, lower revenue after centralized procurement
- Cash and equivalents $41.6M vs $49.2M, operating cash outflow $17.5M for nine months
- F351 NDA decision expected by end-2026 or Q1 2027, with Cullgen integration and clinical spending as headwinds
AI summary of the GYRE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers financial results for the three and nine months ended September 30, 2026
- Investor-relevant figures and management commentary are contained in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation released November 5, 2026, signaling refreshed investor messaging
- Exhibit 99.2 contains the substantive presentation, potentially including business, pipeline or strategy updates
Item EX-99.1: Item EX-99.1
- Q3 revenue $32.9M, up 1%; ETUARY sales $31.4M offset lower Etorel and Contiva revenue under China procurement
- Q3 net loss $2.5M, versus $1.9M income; basic EPS $(0.04), reflecting higher operating and other expenses
Item EX-99.2: Item EX-99.2
- Corporate presentation frames China operations and ETUARY revenue as funding for a diversified U.S.-China degrader pipeline
- ETUARY FY26 revenue guidance $100.5M-$111M, supporting capital-efficient research without dilution dependence
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Ying Luo continues as CEO under a new at-will agreement, with $500,000 base salary and $150,000 target 2026 bonus
- Thomas Eastling continues as CFO under a new at-will agreement, with $339,066 base salary and $70,000 target 2026 bonus
Item EX-99.1: Item EX-99.1
- Corporate presentation outlines Gyre’s China-enabled, capital-efficient pipeline across oncology, autoimmune disease, pain and fibrosis
- ETUARY FY26 revenue guidance of $100.5M-$111M provides commercial funding for early-stage research and development
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation released September 1, 2026
- Investor-relevant updates are contained in Exhibit 99.1, including current corporate and strategic information
AI summaries of GYRE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GYRE
Don't miss the next GYRE filing
- Alerts as it files. A push when GYRE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GYRE, by share count.
- Ask anything. An AI agent that reads every GYRE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Weston Claire | A | Aug 3, 2026 | 40,000 | - |
| Kirkby Maxwell | A | Aug 3, 2026 | 40,000 | - |
| Ye Weiguo | Sell | Jun 18, 2026 | 3,000 | $6.35 |
| Ye Weiguo | M | Jun 18, 2026 | 3,000 | - |
| Ye Weiguo | M | Jun 18, 2026 | 3,000 | $0.75 |
| Ye Weiguo | M | Jun 11, 2026 | 2,800 | - |
| Ye Weiguo | Sell | Jun 11, 2026 | 2,800 | $6.17 |
| Ye Weiguo | M | Jun 11, 2026 | 2,800 | $0.75 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $105.8M | $116.6M |
| Gross Profit | - | $101.9M | - |
| Operating Income | - | $16.2M | $11.5M |
| Net Income | - | $17.9M | $9.9M |
| Gross Margin | - | 96.3% | - |
| Op. Margin | - | 15.3% | 9.9% |
| Net Margin | - | 16.9% | 8.5% |
| Balance Sheet | |||
| Total Assets | $116.5M | $125.4M | $166.1M |
| Equity | -$15.8M | $63.3M | $106.0M |
| ROE | - | 28.3% | 9.3% |
| Per Share | |||
| EPS | $-1.41 | $0.05 | $0.02 |
| Cash Flow | |||
| Operating CF | - | -$3.6M | $1.0M |
| CapEx | - | $2.3M | $1.2M |
Source: XBRL data in GYRE THERAPEUTICS, INC. (GYRE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate GYRE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 15 | $25.2M |
| Q2 2026 | 16 | $17.9M |
| Q1 2026 | 15 | $16.4M |
| Q4 2025 | 13 | $17.1M |
| Q3 2025 | 13 | $16.6M |
| Q2 2025 | 12 | $17.7M |
| Q1 2025 | 12 | $10.8M |
| Q4 2024 | 7 | $7.0M |
- Vanguard Capital Management LLC+589.8K (+67%)
- BlackRock+181.1K (+18%)
- Northern Trust+20.2K (+12%)
- Bank of America Corp+15.9K (+127%)
- Millennium Management+1.6K (+9%)
- Goldman Sachs Group−26.3K (-30%)
- Vanguard Portfolio Management LLC−16.8K (-14%)
- Morgan Stanley−12.4K (-30%)
- Wells Fargo & Co−12.1K (-74%)
- Citigroup−7.8K (-91%)
- FMR LLC (Fidelity)−15.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 103 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GYRE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
GYRE SEC filings: frequently asked questions
Which institutions hold GYRE stock?
As of September 30, 2026, the largest GYRE THERAPEUTICS, INC. (GYRE) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($10.8 million), BlackRock ($8.6 million), State Street Corp ($1.8 million), Northern Trust ($1.4 million), Vanguard Portfolio Management LLC ($786,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GYRE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), GYRE THERAPEUTICS, INC. (GYRE) reported revenue of $116.6 million (up 10.2% from FY2024) and net income of $9.9 million. Diluted EPS was $0.02. The figures come from the XBRL data in the 10-K.
What did GYRE report in its latest 8-K?
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Press release covers financial results for the three and nine months ended September 30, 2026.
What are the latest GYRE SEC filings?
GYRE THERAPEUTICS, INC. (GYRE) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on August 4, 2026.
What is GYRE's SEC CIK number?
GYRE THERAPEUTICS, INC. (GYRE)'s SEC Central Index Key (CIK) is 1124105. EDGAR lists every GYRE filing under that number.
Ask anything about GYRE
The research agent reads GYRE's filings, financials, insider trades and 13F holders, then answers with sources.